On January 28, 2000, Pfizer filed US Patent 6372224 for a “spike protein virus vaccine for the canine coronavirus.”
Research began in 1999, funded by Fauci (actually the American taxpayers), at the University of North Carolina at Chapel Hill which led to the April 19, 2002 US Patent 7279327 to create a “infectious replication defective coronavirus” to “target the human lung epithelium.” That’s not a vaccine, that’s a patent on a virus.
“In other words, we made SARS,” Martin said. “And we patented it on April 19, 2002 before there was ever any alleged outbreak in Asia, which as you know, followed that by several months…. (It) was not only engineered but could be synthetically modified in the laboratory, using nothing more than gene sequencing technologies, taking computer code and turning it into a pathogen, or an intermediate of the pathogen, and that technology was funded exclusively in the early days, as a means by which we could actually harness coronavirus as a vector to distribute HIV vaccine.”
That 2002 patent, by the way, transferred from UNC Chapel Hill to the NIH in 2018 and in 2019 “UNC Chapel Hill, NIAID and Moderna began the sequencing of a spike protein vaccine, a month before an outbreak ever happened” for COVID-19, Martin said.
The CDC filed for US Patent 7220852 in April 2003 and a series of derivative patents, like 7776521, were filed not only covering the SARS coronavirus gene sequences but also the detection tools, and the CDC paid bribes to keep the research private according to Martin.
“If you actually both own the patent on the gene itself, and you own the patent on its detection, you have a cunning advantage to being able to control 100% of the provenance of not only the virus itself, but also its detection, meaning you have entire scientific and message control,” Martin said.
CDC patent filings from 2003, 2005 and 2006 all show 89 to 99 percent “sequence overlaps” with COVID-19. Similar to Moderna developing a coronavirus vaccine months before a COVID-19 outbreak. In 2008, the Defense Advanced Research Projects Agency showed interest in coronaviruses being used as a biological weapon, and patent 9193780 emerged, and between 2008 and 2019 there have been 73 patents related to the so-called “novel” elements of COVID-19.
Moderna was given insider information, according to Martin, months before COVID-19 emerged as what happened in 2003 and Sequoia Pharmaceuticals, part of the holdings of Pfizer and Johnson & Johnson, which obtained patent 7151163 before a virus was known. Martin said: “It is not physically possible for you to patent a thing that treats a thing that had not been published,
because CDC had paid to keep it secret.”
In March of 2019, Moderna began development of a COVID-19 “vaccine” and amended its patent application multiple times “to specifically make reference to an ‘intentional or… deliberate release’ of coronavirus,” Martin said.